Company Description
Microbot Medical Inc., a clinical-stage medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the United States.
The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations.
It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures.
Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Harel Gadot |
Contact Details
Address: 175 Derby Street, Bld. 27 Hingham, Massachusetts 02043 United States | |
| Phone | 781-875-3605 |
| Website | microbotmedical.com |
Stock Details
| Ticker Symbol | MBOT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000883975 |
| CUSIP Number | 59503A204 |
| ISIN Number | US59503A2042 |
| Employer ID | 94-3078125 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Harel Gadot | Co-Founder, President, Chief Executive Officer and Chairman |
| Rachel Vaknin | Chief Financial Officer |
| Dr. Simon Sharon MBA, MSc | Chief Technology Officer and GM of Microbot Israel |
| Dr. Juan Diaz-Cartelle | Chief Medical Officer |
| Michal Ahuvia | Director of Operations |
| Paul Mullen | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 8-K | Current Report |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | 8-K | Current Report |
| Apr 17, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 8, 2025 | 424B3 | Prospectus |